Position Paper on Treatment of Hepatitis C in Romania 2017. Part Two
Background & Aims
Hepatitis C virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%. New treatments have become available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country.
A group of recognized experts was created who screened the available literature and the major available guidelines. A list of items requiring attention was created and these were discussed and rated. Decisions were taken by consensus.
We present here the second part of the Society’s recommendations for chronic HCV infection treatment. An agreement between experts was reached regarding the therapy of the special categories of patients infected with HCV, complications and monitoring of the therapy, follow-up of the patients who reached sustained virologic response and re-treatment of the patients with therapy failure.
This Position Paper represents a guide for the assessment and the therapy of HCV infection. The recommendations are in concordance with other guidelines but are applied to real-life conditions in Romania.
Key words: Hepatitis C virus; guideline; diagnosis; treatment; direct antiviral agents; national strategy; viral hepatitis C
Also see part 1 of this guideline: https://www.ueg.eu/education/document/position-paper-on-treatment-of-hepatitis-c-in-romania-2017-part-one/203026/
This item can be cited as: J Gastrointestin Liver Dis, September 2017 Vol. 26 No 3: 309-317; PMID 28922445
You may be interested in:
- Position Paper
- Standards and Guidelines
UEG Week Pathway